Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1997-10-24
2000-11-14
Nazario-Gonzalez, Porfirio
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
560312, 562621, 562623, A01N 3728, C07C23914
Patent
active
061471143
DESCRIPTION:
BRIEF SUMMARY
FIELD OF INDUSTRIAL APPLICATION
The invention relates to new highly water-soluble compounds, which inhibit matrix metalloproteinases (MMPs) derived from vertebrates and/or tumor necrosis factor-.alpha. (TNF-.alpha.) converting enzyme, preparation intermediates thereof and a process for the preparation thereof.
BACKGROUND ART
MMPs which belong to endo proteinases containing zink are involved in the decomposition of an extra-cellular matrix in a connective tissue. Up to now, it is known that there exist ten-odd MMPs, and the expression of these enzymes are strictly controlled in healthy volunteers. However, an abnormal aggravation of MMPs is observed in cases such as chronic rheumatoid arthritis, osteoarthritis, periodental disease, corneal ulcer, various kinds of bullosis (epidermolisis bullosa hereditaria, epidermolisis bullosa acquisita, porphylia cutanea tarda, bullos penphigoid, pemphigus vulgaris), intractable skin ulcer (bedsore, skin ulcer in radiotherapy, skin ulcer in diabetes mellitus, skin ulcer in arteriosclerotic obliteration), wound (external injury or burn), osteoporosis, cancer metasis and the like, and these are considered to participate in the destruction of the extra-cellular matrix. [D. Brown et al., Current Eye Research, 12, 571(1993)/Y. Okada et al., Virchows Archiv. B, Cell Pathol., 59, 305(1990)/W. G. Stetler-Stevenson, Cancer Metastasis Reviews, 9, 289(1990)/H. Birkedal-Hansen et al., Critical Reviews in Oral Biology and Medicine, 4(2),197(1993)] On the contrary, TNF-.alpha. is produced as a membrane-bound type precursor of molecular weight 26K, and in case of the excess of an extra-cellular release is considered the occurrence of diseases such as sepsis, chronic rheumatoid arthritis or the like. Recently, it was reported that the enzyme (TNF-.alpha. converting enzyme) inducing the release of TNF-.alpha. was a metalloproteinase whose activity was controlled by a MMPs inhibitor. [A. J. H. Gearing et al., Journal of Leukocyte Biology, 57, 774(1995), K. M. Mohler et al., Nature, 370, 218(1994), G. M. NcGeehan et al., Nature, 370, 558(1994)]
Accordingly, in the above diseases, inhibiting the action of these enzymes becomes an effective method of therapy. However, as the compounds having MMPs inhibitory activities are known the compounds divided into four families which are phosphonic acid derivatives, hydroxamic acid derivatives, derivatives having mercapto group and derivatives having carboxyl group. Especially, on the hydroxamic acid derivatives are proposed compounds having various skeletons (see U.S. Pat. No. 4,599,361, EP, 575844 A2, U.S. Pat. No. 5,412,145, WO, 92/13831, U.S. Pat. No. 5,183,900, WO, 94/02447, EP, 606046 A1 and GB 2268933 A), and many of these compounds have highly inhibitory activities for various kinds of MMPs. However, each of these compounds is poor in its water-solubility and their administration methods are limited. For example, in case of applying these compounds as injections (aqueous solution), medicaments of high concentration cannot be prepared. Furthermore, in case of administering injections into joint, if there is a particle not less than 50 .mu.m, the occurrence of a synovial inflammation is known, therefore, it becomes a necessary condition for a compound to be completely dissolved state. In the known compounds, such an administration is impossible, and it is a present situation that they are not effectively utilized as therapeutic agents.
DISCLOSURE OF THE INVENTION
The inventors gave attention to the hydroxamic acid derivatives having highly inhibitory activities, and as the result of making an extensive studies to enhance the availability, we accomplished the invention by finding out new hydroxamic acid derivatives whose water-solubility was dramatically increased compared with that of the above compounds' group.
Accordingly, the invention provides compounds of general formula (I) ##STR2## (wherein R.sup.1 is a hydrogen atom, or a hydroxyl, aryl(C.sub.1 -C.sub.6)alkylene or --A--SOn--B group (A is a (C.sub.1 --C.sub.6) alkylene group; B is
REFERENCES:
patent: 4599361 (1986-07-01), Dickens et al.
patent: 5183900 (1993-02-01), Galardy et al.
patent: 5300674 (1994-04-01), Crimmin et al.
patent: 5412145 (1995-05-01), Crimmin et al.
patent: 5442110 (1995-08-01), Isomura et al.
patent: 5514716 (1996-05-01), Gowravaram et al.
Database CAPLUS on STN, Acc. No. 1993:39408, Beckett et al., `Preparation of amino acid amide hydroxanates as collagenase ihibitors.` EP 498665 A1, abstract, 1993.
D. Brown, et al, Current Eye Research vol. 12 No. 6 1993, 571-581, Keratoconus corneas: increased gelatinolytic activity appears affter modifications of inhibitors.
Cancer and Metastasis Reviews 9:289-303, 1990, 1990 Kluwer Academic Publishers Printed in the Netherlands, Type IV collagenases in tumor invasion and metastasis, William G. Stetler-Stevenson Laboratory of Pathology, National Cancer Institute, NAtional Institutes of HEalth, Bethesda, MD, USA.
Critical Reviews in Oral Biology and Medicine, 4(2): 197-240 (1993) Matrix Metalloproteinases: A Review*, H. Birkedal-Hansen et al, Department of Oral Biology, REsearch Center in Oral Biology.
Matrix Metalloproteinases and Processing of Pro-TNF-, A.J.H. Gearing et al, Neures Limited and British Biotech, Oxford, United Kingdom, Journal of LEukocyte Biology vol. 57, May 1995, pp. 774-777.
Letter to Nature, Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing, Kendal M. Mohler, et al, Immunex Research and Development Corp. pp. 218-220.
Letters to Nature, Regulation of tumor necrosis factor-processing by a metalloproteinase inhibitor, Gerard M. McGeehan et al, Glaxco Inc. Research Institute, Research Triangle Park, North Carolina 27709, USA, pp. 558-561.
J. Org. Chem. 1982, 47, 4928-4933, Enantioselective Syntheses of 3-Substituted 4-(Alkoxycarbonyl)-2-azetidinones from Malic Acid, MArvin J. Miller, et al, Department of Chemistry, University of Notre Dame, Notre Dame, Indians 46558.
Helvetica Chimica Acta-vol. 66, Fasc. 5(1983)-Nr. 128, 128, Angiotensin II Analogues, Part II, Synthesis and Incorporation of the SUlfur-Containing Aromatic Amino Acids, by Emanuel Escher, et al.
Journal of Hepatology, 1993; 18: 328-334, 1993 Elseview Scientific Publishers Ireland Ltd., Serum collagenase activity in patients with chronic liver diesase, Yoshikazu Murawaki et al.
Analytical Biochemistry 143 30-34, (1984), Fluorescein Isothiocyanate-Labeled Casein Assay for Proteolytic Enzymes, Sally S. Twining, Department of Biochemistry and Ophthalmology, Medical College of Wisconsin, Milwaukee, Wisconsin 53226.
Virchows Archiv B Cell Pathol (1990) 59-305-312, Virchows Archiv B Cell Pathology Including Molecular Pathology Springer-Verlag 1990, Immumohistochemical demonstration of collagenase and tissue inhibitor of metalloproteinases (TIMP) in synovial lining cells of rheumatoid synovium, Yasumori Okada et al.
Fujisawa Tetsunori
Hongo Tomoko
Igeta Katsuhiro
Ito Hajime
Morikawa Tadanori
Davis Brian J.
Fuji Yakuhin Kogyo Kabushiki Kaisha
Nazario-Gonzalez Porfirio
LandOfFree
Highly water-soluble metalloproteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Highly water-soluble metalloproteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Highly water-soluble metalloproteinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2065884